MedTrace Logo

Safety and Efficacy of YB-1113 in Treatment of POI

NCT05494723 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-12-23

No results posted yet for this study

Summary

This phase 1 study is to evaluate the safety and tolerability of YB-1113 administered via intravenous (IV) infusion in the treatment of premature ovarian insufficiency (POI).

Conditions

  • POI

Interventions

DRUG

YB-1113

Human umbilical cord tissue-derived mesenchymal stem cells (hUC-MSC)

Sponsors & Collaborators

  • Bright Cell, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-09
Primary Completion
2028-01-09
Completion
2028-04-09
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05494723 on ClinicalTrials.gov